Northwest Biotherapeutics Inc. (NWBO.OB)
Oncology Corporate Profile
- Products & Overview
- Recent News
HQ Location
7600 Wisconsin Avenue, Suite 750Bethesda, MD 20814
Company Description
Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer.
Website: http://www.nwbio.com
Commercial Products
This company does not have any commercial productsPipeline Products
- Brand
- Generic
- Investigational
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| DCVax® | immunotherapy | Prostate cancer | III | |
| DCVax® | immunotherapy | Glioblastoma Multiforme (GBM) | II | |
| DCVax® | immunotherapy | Non Small Cell Lung Cancer (NSCLC) | I | |
| DCVax® | immunotherapy | Ovarian cancer | I | |
| CXCR4 | anti-chemokine receptor (CXCR4) monoclonal antibody | Various cancer types | Preclinical | |
| DCVax® | immunotherapy | Head & Neck cancer | Preclinical | |
| DCVax® | immunotherapy | Hepatocellular carcinoma (HCC) | Preclinical | |
| DCVax® | immunotherapy | Pancreatic cancer | Preclinical |
View additional information on product candidates here »
Recent News Headlines
[PR Newswire] - Northwest Biotherapeutics, Inc. today announced further positive long-term follow-up data from its prior Phase I and Phase I/II clinical trials, in which patients with newly diagnosed Glioblastoma multiforme , the most rapid and lethal type of brain cancer, were treated with NWBT's DCVax®-Brain personalized immune therapy. Â
[GlobeNewswire] - DALLAS -- MicroStockProfit.com announces an investment report featuring Northwest Biotherapeutics Inc. . The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
(US Oncology) July 14, 2010 - Northwest Georgia Oncology Centers (NGOC), a medical practice dedicated to delivering high quality, cost-effective oncology and hematology services to patients in Northwest Georgia, and US Oncology, Inc., the nation’s leading integrated oncology company, announced today that NGOC has joined the United Network of US Oncology.
[PR Newswire] - Northwest Biotherapeutics, Inc. , developer of the DCVax® personalized cancer vaccines, announced today that during the second quarter it raised funding of $2.65 million from investors.  The funding included $1.75 million in purchases of restricted common stock of the Company by a number of private investors, together with purchases of restricted Common Stock totaling $900,000 by SDS Capital and by Ms.
[PR Newswire] - Northwest Biotherapeutics, Inc. , developer of the DCVax® personalized cancer vaccine, today announced the release of a new detailed report by Pharmaceuticals and Biotech Analyst Dr.
Northwest Biotherapeutics, Inc. , a development stage biotechnology company focused on personalized cancer vaccines to enhance immune system responses to tumors, has retained Market Media Connect as their communications agency of record.  Led from its Los Angeles headquarters, Market Media Connect will support Northwest’s communication objectives as the company moves into the next phase of its development.
Northwest Biotherapeutics, Inc. , a development stage biotechnology company focused on personalized cancer vaccines to enhance immune system responses to tumors, has retained Market Media Connect as their communications agency of record. Â Led from its Los Angeles headquarters, Market Media Connect will support Northwest's communication objectives as the company moves into the next phase of its development.
Northwest Biotherapeutics Inc., which is working on cancer treatments, said Thursday it picked a veteran of Democratic presidential campaigns to serve on its board.
Northwest Biotherapeutics, Inc. today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme .